Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NHS Medtech Demand-Side Should Be Greater Priority, Says UK Industry In AAR Response

Executive Summary

The Accelerated Access Review, part of the UK's renewed push to speed access to innovations for system efficiency, cost savings and outcomes improvements, strikes most of the right notes, but there is still room for improvement in the framework of innovation adoption by the NHS, according to an industry-commissioned response to the review.

You may also be interested in...

UK Outlook 2018: Companies Need To Quantify Brexit Risk And Find A New Place In The World

With the clock running down on Brexit, bemused UK medtechs are ready to seize any information that helps them chart a way forward on trading with the EU in the absence of solid directions from the government. Frustrated by the Brexit vacuum, local manufacturers are actively looking to build businesses beyond the EU and focusing on innovation adoption at home, as ABHI policy director Richard Phillips explains.

UK Outlook 2018: Medtech Readies For Change To FOM System Of Value-Based Procurement

For UK medtech companies, a new NHS value-based procurement system is coming in the shape of the Future Operating Model. ABHI COO Nishan Sunthares explains what the FOM will mean for UK medtechs when it applies fully later this year.

UK Medtech To Leverage Accelerated Access Opportunity, Regardless Of The 'B' Word

The UK devices and diagnostics industries were quick to react to the long-overdue government response to the fall 2016 Accelerated Access Review, a proposal to fast-track innovation into the NHS to the benefit of UK science, patients and the economy. Coinciding with Brexit, it is a fine-sounding plan, but will there be practical follow-through for medtech too?

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts